The Wet AMD and DME Drug Development Summit comes at a critical juncture, as the research community progresses novel drug candidates targeting angiogenesis-driven disease, and a pandemic further exposes the treatment limitations for a global aging population.
The treatment landscape for Wet Age-Related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME) has dramatically changed since the first anti-VEGF therapies were approved for ocular neovascularization. However, the industry continues to explore new therapeutic avenues to improve treatment convenience, efficacy and/or reduce the frequency of invasive procedures. The development of new treatments for wet AMD and DME, two indications pursued often in parallel by drug developers, is of strategic importance for many ophthalmology research teams and for the first-time there will be a dedicated, drug development summit for this community.
This event will gather C-Suite and senior leaders of discovery, translational sciences, and clinical development from the likes of Boehringer Ingelheim, Doheny Eye Institute, Aerpion Therapeutics, Genentech, ForwardVue Pharma, Ocugen and more to give insight into their ongoing drug programs and share their knowledge on how we can accelerate the breakthrough of less-evasive and longer duration therapeutics. Key discussions to take place at this exclusive forum will include future directions with novel monotherapies or combinations (including with anti-VEGF agents) to address the clinical burden and unpredictable response to treatment, expanding therapeutic options for patients with earlier stage disease, and generating clinical data to address stakeholder (both regulatory and clinicians) expectations in terms of safety and benefit/risk.
Our industry-led speaker faculty will give comprehensive insight into current and emerging angiogenesis- and inflammation directed therapies for these two ophthalmic conditions, which incorporate inducing longer-term VEGF suppression, non-VEGF and VEGF independent pathways and gene therapy applications. The focus of this content and the wider networking at this 3-day digital meeting will be to share clinical approaches in identifying relevant patient populations and delivering them a higher standard of care.
Gain insight into next generation targets, the current industry pipeline and overcome specific clinical development challenges. If you are investing in research to challenge these blockbuster therapeutics and develop pioneering, safe and efficacious treatment options, then make sure you secure your place at the only industry-led forum in this field.
The treatment landscape for Wet Age-Related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME) has dramatically changed since the first anti-VEGF therapies were approved for ocular neovascularization. However, the industry continues to explore new therapeutic avenues to improve treatment convenience, efficacy and/or reduce the frequency of invasive procedures. The development of new treatments for wet AMD and DME, two indications pursued often in parallel by drug developers, is of strategic importance for many ophthalmology research teams and for the first-time there will be a dedicated, drug development summit for this community.
This event will gather C-Suite and senior leaders of discovery, translational sciences, and clinical development from the likes of Boehringer Ingelheim, Doheny Eye Institute, Aerpion Therapeutics, Genentech, ForwardVue Pharma, Ocugen and more to give insight into their ongoing drug programs and share their knowledge on how we can accelerate the breakthrough of less-evasive and longer duration therapeutics. Key discussions to take place at this exclusive forum will include future directions with novel monotherapies or combinations (including with anti-VEGF agents) to address the clinical burden and unpredictable response to treatment, expanding therapeutic options for patients with earlier stage disease, and generating clinical data to address stakeholder (both regulatory and clinicians) expectations in terms of safety and benefit/risk.
Our industry-led speaker faculty will give comprehensive insight into current and emerging angiogenesis- and inflammation directed therapies for these two ophthalmic conditions, which incorporate inducing longer-term VEGF suppression, non-VEGF and VEGF independent pathways and gene therapy applications. The focus of this content and the wider networking at this 3-day digital meeting will be to share clinical approaches in identifying relevant patient populations and delivering them a higher standard of care.
Gain insight into next generation targets, the current industry pipeline and overcome specific clinical development challenges. If you are investing in research to challenge these blockbuster therapeutics and develop pioneering, safe and efficacious treatment options, then make sure you secure your place at the only industry-led forum in this field.
